In one of the largest studies of its kind, JDRF has partnered with iCo Therapeutics to investigate a potential new drug that could, if successful, broaden treatment options for people living with DME. The Phase II trial, led and coordinated by Johns Hopkins University investigators, is currently recruiting participants. To inquire about participation, please contact Dr. Quan Dong Nguyen or click here.
You could call them brothers-in-arms in the battle against type 1 diabetes (T1D): Maarten de Groot, founder and president of JDRF Netherlands, our organization’s newest international affiliate; and Bart Roep, M.D., Ph.D., a clinical immunologist who leads a T1D research team at Leiden University Medical Center, in the Netherlands. Dr. Roep is one of the […]
By Susan Learner Barr, M.S., R.D. There’s no end to what you can learn when visiting our nation’s capital. On February 18, more than 600 people, all sharing a connection to type 1 diabetes (T1D), attended the 2012 JDRF Type 1 Diabetes Research Summit hosted by the JDRF Capitol Chapter. A letter in the summit […]
By Michelle A. Cissell, Ph.D. Women know the importance of taking extra care of themselves before and during pregnancy—for the optimal health of their babies, as well as for their own well-being. For women with type 1 diabetes (T1D), diligent self-management both before and during pregnancy is especially crucial, as high blood glucose levels increase […]
By Jeffrey Brewer When JDRF was asked to submit an article to Diabetes, a medical journal of the American Diabetes Association (ADA), our organization’s leaders recognized the superb opportunity offered by this request. As a result, “Juvenile Diabetes Research Foundation: Mission, Strategy, and Priorities” was published in the January 2012 issue ofDiabetes in the journal’s “Perspectives in […]
Taking oral insulin in combination with low-dose anti-CD3 results in long-term reversal of type 1 diabetes in mice whose immune systems specifically attack insulin. The findings, if translated to humans, would help not only to identify people who are most likely to benefit from the therapy, but also to determine whether the therapy is working.
Previous research identified high levels of the enzyme plasma kallikrein in patients with diabetic macular edema, a condition that can cause impaired vision or blindness. JDRF-funded studies by KalVista Pharmaceuticals aim to identify new therapies that will reduce levels of plasma kallikrein and preserve the eyesight of people with T1D.
Researchers supported by JDRF recently characterized for the first time the nature of the encounter between killer T cells and their targets—the insulin-producing beta cells in the pancreas. Using an actual T cell that was replicated or “cloned” from a patient with type 1 diabetes (T1D), the
researchers provided valuable evidence about the interaction that takes place on a molecular level and contributes to the autoimmune attack that destroys beta cells. These findings can help guide the development of targeted therapies for the prevention of T1D.
Researchers recently demonstrated for the first time a direct association between human beta cell destruction and CD8 T cells, which are cells that play an important role in the body’s immune system. This autoimmune “attack” is a hallmark of T1D and it results in the destruction of insulin-producing beta cells in the pancreas. In their investigation, the researchers used human tissue samples from the pancreases of T1D organ donors obtained through nPOD, a JDRF collaborative research project. This new study provides evidence that CD8 T cells are present in the islets of the pancreas that contain beta cells. These findings are important for future research on preserving beta-cell function and establishing biomarkers for therapies for T1D.
Consistent with its leadership role in T1D research, JDRF is prioritizing the investigation of biomarkers. We are advancing the knowledge about the direction and needs of research in this critical area, with the goal of providing vital information to reliably measure or predict disease progression in individuals with T1D and to indicate their responsiveness to therapies. Supporting the development of biomarkers for T1D could provide industry with tools to allow for more efficient and attractive incentives to pursue therapies for the disease.